Search clinical trials for: Olmesartan Medoxomil Tablets 40 mg

Total 2304 results

Mylan Pharmaceuticals Inc

Completed

Fasting Study of Olmesartan Medoxomil Tablets 40 mg and Benicar® Tablets 40 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fed Study of Olmesartan Medoxomil Tablets 40 mg and Benicar® Tablets 40 mg

Healthy

United States
Torrent Pharmaceuticals Limited

Completed

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Olmesartan Medoxomil Tablet Under Fasting Conditions

Healthy Subjects
Torrent Pharmaceuticals Limited

Completed

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Olmesartan Medoxomil Tablets Under Fed Conditions

Healthy Subjects
Mylan Pharmaceuticals Inc

Completed

Fed Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg

Healthy

United States
Lee's Pharmaceutical Limited

Completed

Azilsartan in Chinese Patients With Mild and Moderate Hypertension

Hypertension

China
Pharmtechnology LLC
Altasciences Company, Inc.

Unknown

A Bioequivalence Study of Two Different Formulations of Olmesartan Medoxomil/ Hydrochlorothiazide After a Single Oral Dose Administration Under Fasting Conditions

Bioequivalence

Canada
Pharmtechnology LLC
Altasciences Company, Inc.

Completed

The Bioequivalence Study of Two Different Formulations of Olmesartan Medoxomil After a Single Oral Dose Administration Under Fasting Conditions.

Bioequivalence

Canada
Daiichi Sankyo, Inc.
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension

Essential Hypertension

France, Poland, Ukraine, Germany, Spain, Bulgaria, Czechia
Daiichi Sankyo Co., Ltd.

Completed

ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial

Type 2 Diabetes Mellitus | Diabetic Nephropathy | Proteinuria

Japan, China
Brainfarma Industria Química e Farmacêutica S/A

Not yet recruiting

Efficacy and Safety Study of the Fixed-dose Combination of Olmesartan + Indapamide When Compared to the Isolated Drugs in the Treatment of Hypertension. (OLINDA)

Hypertension | Hypertension,Essential
Sankyo Pharma Gmbh

Completed

Olmesartan in Essential Hypertension

Essential Hypertension

Austria, Germany, Italy, Netherlands, Portugal, Spain, Switzerland, United Kingdom
Daiichi Sankyo, Inc.

Completed

Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension

Essential Hypertension

France, Poland, Ukraine, Belgium, Germany, Spain, Bulgaria, Romania, Denmark, Russian Federation, Netherlands, Austria, Slovakia, Czechia
Sankyo Pharma Gmbh

Completed

Olmesartan Medoxomil in Diabetes Mellitus

Cardiovascular Disease | Diabetes Mellitus, Type 2 | Kidney Disease

Germany
Daiichi Sankyo, Inc.

Completed

Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure

Hypertension

United States, Colombia, Argentina, Peru, Brazil, Kenya, Chile, South Africa, India, Zambia, Uganda
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Effect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic Syndrome (VAMOS)

Hypertension | Metabolic Syndrome

Germany
Daiichi Sankyo, Inc.
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension

Essential Hypertension

Belgium, Germany, Netherlands, Slovakia
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension

Essential Hypertension

China
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Terminated

Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24 (OLMEBNP)

Chronic Heart Failure | High Blood B-type (or Brain) Natriuretic Peptide (BNP) Level

Germany, France, Netherlands
Tohoku University

Completed

Supplemental Benefit of Angiotensin Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan (SUPPORT)

Chronic Heart Failure

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of Olmesartan Medoxomil (CS-866) in Patients With Chronic Glomerulonephritis or Diabetic Nephropathy

Diabetic Nephropathy | Chronic Glomerulonephritis

Japan
Central South University

Completed

Drug Interaction Study of Olmesartan in Healthy Chinese Volunteers

Drug Interaction of Olmesartan in Healthy Chinese Volunteers

China
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection (ArtStiff)

Hypertension | Metabolic Syndrome

Italy, Belgium, Germany
Virginia Polytechnic Institute and State University
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Angiotensin II Blockade and Inflammation in Obesity (ARB)

Hypertension | Overweight | Prehypertension | Obese
Research Institute for Complex Problems of Cardiovascular...

Completed

Azilsartan Medoxomil in Hypertensive pAtients With Stable Ischemic Heart Disease and DiabEtes MEllitus. (AcADEME)

Diabetes Mellitus | Arterial Hypertension | Stable Chronic Angina

Russian Federation
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension

Hypertension

United States, Mexico, Argentina
Daiichi Sankyo, Inc.

Completed

A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis

Atherosclerosis
Pfizer

Completed

Post-Marketing Surveillance Of Olmesartan Medoxomil In Combination With Hydrochlorothiazide

Hypertension
Daiichi Sankyo, Inc.

Completed

Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension

Essential Hypertension

Italy, Poland, Ukraine, Germany, Spain, Bulgaria, Romania, Denmark, Belgium, Netherlands, Russian Federation, Hungary, Slovakia, Czechia, Latvia
Daiichi Sankyo, Inc.

Completed

An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension

Hypertension

United States
Takeda

Completed

Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease

Safety

Ukraine, Germany, Poland, Bulgaria, Netherlands, Lithuania, Slovakia, Latvia
Daiichi Sankyo Co., Ltd.

Completed

Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension

Essential Hypertension

Japan
Daiichi Sankyo, Inc.

Completed

Olmesartan Pediatric Pharmacokinetic (PK) Study

Hypertension

United States
Chinese PLA General Hospital

Unknown

Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis and Epicardial Adipose Tissue(EAT)

Coronary Atherosclerosis

China
Shenzhen People's Hospital

Recruiting

s086 Tablets in the Treatment of Mild to Moderate Essential Hypertension

Essential Hypertension

China
Sankyo Pharma Gmbh

Completed

Olmesartan Medoxomil and Diabetic Nephropathy

Type 2 Diabetes Mellitus | Diabetic Nephropathy | Proteinuria | Renal Disease

Poland, Spain, Estonia, Czech Republic, Germany, Slovakia, Netherlands
Seoul National University Bundang Hospital

Completed

Effect of Olmesartan on Angiotensin(1-7) Levels and Vascular Functions in Diabetes and Hypertension (Ang(1-7))

Hypertension | Diabetes Mellitus, Type 2 | Angiotensin/Renin/Aldosterone Hypertension

Korea, Republic of
Daiichi Sankyo, Inc.

Completed

An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes

Hypertension

United States
Daiichi Sankyo, Inc.
Shanghai Sankyo Pharmaceuticals Co., Ltd.

Completed

Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension

Essential Hypertension

China
Daewoong Pharmaceutical Co. LTD.

Completed

A Clinical Trial to Evaluate the Efficacy and Safety of Olmesartan/Amlodipine/Rosuvastatin Combination Treatment in Patients With Concomitant Hypertension and Hyperlipidemia

Hypertension | Hyperlipidemias

Korea, Republic of
EMS

Not yet recruiting

Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control

Arterial Hypertension
Daiichi Sankyo, Inc.

Completed

An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With Hypertension

Hypertension

United States
Daiichi Sankyo Co., Ltd.

Completed

Calcium Channel Blockers (CCBs) or Diuretics as an Add-on to Olmesartan Medoxomil in Hypertension

Hypertension

Japan
Daiichi Sankyo, Inc.

Completed

The Relative Effects of Olmesartan Medoxomil, Irbesartan and Valsartan on the Activity of the Blood Pressure Control System in Healthy Subjects

Healthy
Daiichi Sankyo, Inc.
Integrium

Completed

A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure (BP CRUSH)

Hypertension

United States
Bausch Health Americas, Inc.

Completed

Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis

Liver Cirrhosis

United States, Russian Federation
EMS

Not yet recruiting

Efficacy and Safety of Olmesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control

Essential Arterial Hypertension
Eisai Inc.

Completed

Subject Variability in Two Lots of E5501 Administered to Fed and Fasted Healthy Subjects

Purpura, Thrombocytopenic, Idiopathic | Chronic Thrombocytopenia | Acute Idiopathic Thrombocytopenic Purpura

Netherlands
Istituto Oncologico Veneto IRCCS

Completed

Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS

Glioblastoma Multiforme

Italy

3

Subscribe